Valvular Heart Disease in Women Registry
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- This is an observational study: the protocol does not assign a study treatment.
- Who it may be relevant to
- Registry conditions: Valve Disease, Heart, Gender Bias, Guideline Adherence, Guideline Implementation. Basic parameters: from 18 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- Egypt, Portugal
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Overview
Valvular heart disease (VHD) is a major global health issue. Untreated rheumatic heart disease persists in many regions, preventable with timely care. Higher-income countries face rising calcific valve disease from aging, worsened by VHD complications, like infective endocarditis, resulting in higher morbidity/mortality. Gender disparities in VHD remains understudied, despite inequalities in risks, diagnosis, and treatment. Prevalence varies by gender, but uneven diagnostics and therapies obscure realities. This registry will examine gender disparities from hospital admission to first outpatient follow-up, recruiting both men and women to investigate and report the study objectives.
Detailed description
Valvular heart disease (VHD) is a major global public health problem (1). Many regions of the world continue to grapple with the adverse consequences of untreated rheumatic heart disease, a condition that is largely preventable with timely access to diagnosis and treatment (2, 3). In turn, middle- and high-income countries have experienced a rise in the prevalence of calcific aortic and mitral disease, owing in part to population ageing (3). This public health problem is further compounded by high rates of infective endocarditis, which is associated with substantial morbidity and mortality. Yet, considerations of gender disparities have not taken centre stage in VHD research. This is despite evidence of major healthcare disparities in socioeconomic and medical risk factors, access to diagnosis, and provision of appropriate treatment (4-7). The prevalence of VHD varies by gender, but diagnostic evaluations are not equitable across the groups, which makes the true prevalence less clear. The delivery of evidence-based treatments for VHD is not equitable (8). The aim of this registry will be to examine gender differences in VHD from the time point of admission to the hospital (either elective or urgent admission) up to the first follow-up in an outpatient clinic. We will recruit both men and women in order to analyse the gender disparities.
Primary outcome measures
- Disparities in Valvular Heart Disease (VHD) Treatment [Time frame: One year]
- Disparities in Valvular Heart Disease Management [Time frame: One year]
- Adherence to/Compliance with European Society of Cardiology (ESC) Guidelines for Management of Valvular Heart Disease. [Time frame: One Year]
Secondary outcome measures (3)
- Time from Diagnosis to Guideline-Directed Therapy: Comparison Between Women and Men [Time frame: One Year]
- Time from Symptom Onset to Presentation at Tertiary Center: Comparison Between Women and Men [Time frame: One Year]
- Procedural Complications: Comparison Between Women and Men [Time frame: One Year]
Eligibility criteria
Inclusion criteria
- Adult patients with diagnosis of any VHD according to the current ESC guidelines.
- Admission to the VHD-W Registry collaborating center.
Exclusion criteria
- Age less than 18 years old.
- Inability to provide informed consent per local institutional and regulatory requirements.
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Observational model
- Other
Study locations
Egypt · 1 center
- Aswan Heart Centre — Aswān
Portugal · 1 center
- University of Lisbon — Lisbon
Identifiers
NCT: NCT07196930 · VHD-W Registry